A protocol for the evaluation of new psychoactive drugs in man.
A protocol is presented that has proven effective in the determination, in man, of the psychotomimetic potency and qualitative nature of action of a new drug. It involves a minimum of animal screening, but relies heavily upon the use of experienced human subjects. This procedure has been successful in the discovery of over 200 novel CNS-active agents.
D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D006213:Hallucinogens / Q000494:pharmacology; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy; D011619:Psychotropic Drugs / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D012107:Research Design; D012677:Sensation / Q000187:drug effects
D000928:Antidepressive Agents; D006213:Hallucinogens; D011619:Psychotropic Drugs